Literature DB >> 9836669

Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.

C Counsell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836669      PMCID： PMC1114394     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

2.  Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.

Authors:  O Mäki-Ikola; O Kilkku; E Heinonen
Journal:  BMJ       Date:  1996-03-16

3.  Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Authors:  V V Myllylä; K A Sotaniemi; P Hakulinen; O Mäki-Ikola; E H Heinonen
Journal:  Acta Neurol Scand       Date:  1997-04       Impact factor: 3.209

4.  The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.

Authors:  J P Larsen; J Boas
Journal:  Mov Disord       Date:  1997-03       Impact factor: 10.338

5.  Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1998-03       Impact factor: 10.422

6.  Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Authors:  C W Olanow; V V Myllylä; K A Sotaniemi; J P Larsen; S Pålhagen; H Przuntek; E H Heinonen; O Kilkku; R Lammintausta; O Mäki-Ikola; U K Rinne
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

7.  Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim; V Hars; J Marton
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575
  7 in total
  2 in total

Review 1.  Evaluating drug treatments for Parkinson's disease: how good are the trials?

Authors:  Keith Wheatley; Rebecca L Stowe; Carl E Clarke; Robert K Hills; Adrian C Williams; Richard Gray
Journal:  BMJ       Date:  2002-06-22

2.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.

Authors:  Natalie J Ives; Rebecca L Stowe; Joanna Marro; Carl Counsell; Angus Macleod; Carl E Clarke; Richard Gray; Keith Wheatley
Journal:  BMJ       Date:  2004-08-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.